Skip to content

A cluster randomized trial of ActeevTM system compared with standard system to prevent Severe Acute Respiratory Syndrome Coronavirus 2 in health care workers.

A cluster randomized trial of ActeevTM system, (ActeevTM N95 masks YQD8008 during the shifts plus ActeevTM fabric masks in community) compared with the standard system, (standard N95 masks during shifts plus fabric masks in community) in preventing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) in health care workers.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037467
Enrollment
1600
Registered
2021-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: ActeevTM system which includes ActeevTM N95 masks YQD8008 during shifts and ActeevTM fabric masks in community.: Participants in Arms 1 will wear ActeevTM N95 masks YQD8008 during 8-hou

Sponsors

Ascend Performance Materials Operations LLC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A subject will be considered eligible for inclusion in this study only if ALL of the following criteria apply: 1.Health care workers and allied health care staff working in COVID wards, COVID ICU, Non COVID ICU (This will include all specialty ICUs in the hospital), Casualty/Emergency, Operation Theatre and Pathology lab of the hospital to be considered for recruitment. 2.Health care workers and allied health care staff involved in performing high risk procedures like suctioning, intubation, nebulized medications, chest physiotherapy, other aerosol generating procedures and handling pathology samples to be considered for recruitment 3.Negative COVID 19 RT-PCR test within last 3 days of screening 4.COVID 19 vaccinated or non-vaccinated.

Exclusion criteria

Exclusion criteria: A subject will not be eligible for inclusion in this study if ANY of the following criteria apply: 1.Unable or refused to consent 2.Current respiratory illness, rhinitis and/or allergy 3.Currently participating in any other clinical trial 4.Beard or facial hair

Design outcomes

Primary

MeasureTime frame
Number of cases with laboratory-confirmed for viral SARS CoV 2 respiratory infection using RT-PCR with or without two or more respiratory symptoms or one respiratory symptom and/or a systemic symptomTimepoint: Test will be repeated every 2 weeks to identify the number of cases with SARS CoV 2 infection

Secondary

MeasureTime frame
1.Number of cases with Clinical Respiratory illness defined as two or more respiratory symptoms or one respiratory symptom and/or a systemic symptom along with laboratory confirmed viral and bacterial respiratory infection other than SARS CoV 2 (Including respiratory syncytial virus (RSV), human metapneumovirus(hMPV), influenza A (H3N2), (H1N1) pdm09, influenza B, parainfluenza viruses 1 to 4, influenza C, rhinoviruses, severe acute respiratory syndrome (SARS) associated coronavirus (SARS CoV), coronaviruses 229E, NL63,OC43 and HKU1, adenoviruses and Bacteria Bordetella pertussis, Bordetella parapertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae). 2.Adverse events related to wearing a mask, a safety issue (Skin rash, difficulty breathing, pressure on nose, allergies or any other event reported by participant). 3.Poor adherence with mask wearing Drug-consumption/Concomitant medication, in particular antibiotics. 4.Sick-leave from work Timepoint: Test will be performed only if patient have symptoms & SARS CoV 2 test is negative

Countries

India

Contacts

Public ContactDr Vikram Gopal

Ascend Performance Materials Operations LLC

VGopal@ascendmaterials.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026